MONTREAL, May 24, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that its OTC business has launched a new line of omega fish oils based formulations targeting inflammation, heart and vision care.
High End Omega Based Product Line
The Company has launched an initial two omega formulated products to support heart health and vision care: CardiaProtm and VisionProtm, leading the way to a complete line of scientifically formulated products targeting inflammation.
Inflammation, which is a process by which the body's natural immune response seeks to protect us from infection with foreign organisms, such as bacteria and viruses. However, as a result of our environment and modern lifestyles, our immune response remains on a constant “state of alarm” leading to a constant state of immune response leading to inflammation and causing chronic conditions of pain, inflammation and dysfunction. Our new line of health products leverages the inflammation fighting benefits of the omega spectrum of fatty acids through exclusive targeted formulations to support specific health functions such as heart, vision and joints.
Subject to the positive adoption of cannabidiol as a health supplement by the FDA and complete clearance of the legal context in the US, the company’s OTC business plans to leverage the anti-inflammatory and pain reduction benefits of this cannabinoid, which is the center of much expectation from the Health and Wellbeing market.
Abis Hussain, CMO, stated: “We have started the process of shifting towards scientific based formulations, targeting niche and focused product offerings in high demand, such as is the case of inflammation,” Mr. Hussain stated further “Our Heart and Vision formulations will be sold primarily through social media and through some of our major market places. However, we are also pursuing a brick and click strategy thus extending our offering through health stores.”
Update on Push and Pulltm Anti-Aging System
Launched earlier this year, the Company’s Push and Pull Anti-Aging System, targeting the Hispanic market in North America, has been successfully deployed in the Puerto Rican market and the company plans to expand its target to South Florida, Texas, California and Mexico.
The company’s Direct Response Campaigns have been tested in several consumer segments and subject to its successful deployment in these Hispanic markets, it plans to open the product offering to other focused demographics in the US.
Aurelio Useche, CEO Stated: “Our entry into the highly competitive Anti-Ageing Market was a bold move by our team, which is why we focused on specific demographics and to understand their specific needs and shopping habits. The North American anti-aging market is estimated to be an $18 Billion business with a steady 5.2% CAGR growth, and our target is to play a niche role in the space.”
About Relevium Technologies
Relevium is a publicly-traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the Health and Wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products.
Relevium operates through two wholly-owned subsidiaries:
BGX E-Health LLC (BGX): Based in Orlando, Florida, BGX is our OTC business that markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s brands such as Bioganix® are sold at some of the world’s largest retailers including such as Walmart.com and Amazon.com.
Biocannabix Health Corporation (BCX): Based in Montreal, Quebec, BCX is an entrepreneurial venture to establish an integrated medical cannabis company in the Nutraceutical space targeting pediatric support in conjunction with traditional medical therapies.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn